Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Net Margin (2016 - 2025)

Anika Therapeutics has reported Net Margin over the past 16 years, most recently at 4.93% for Q4 2025.

  • Quarterly Net Margin rose 5840.0% to 4.93% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.01% through Mar 2026, up 3924.0% year-over-year, with the annual reading at 0.8% for FY2025, 3886.0% up from the prior year.
  • Net Margin was 4.93% for Q4 2025 at Anika Therapeutics, down from 3.04% in the prior quarter.
  • Over five years, Net Margin peaked at 17.12% in Q2 2021 and troughed at 589.86% in Q4 2023.
  • The 5-year median for Net Margin is 7.58% (2022), against an average of 52.41%.
  • Year-over-year, Net Margin crashed -37170bps in 2023 and then skyrocketed 52653bps in 2024.
  • A 5-year view of Net Margin shows it stood at 30.01% in 2021, then tumbled by -627bps to 218.16% in 2022, then crashed by -170bps to 589.86% in 2023, then soared by 89bps to 63.33% in 2024, then surged by 92bps to 4.93% in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Net Margin are 4.93% (Q4 2025), 3.04% (Q3 2025), and 2.4% (Q2 2025).